Premium
Epstein–Barr virus early‐antigen antibodies before allogeneic haematopoietic stem cell transplantation as a marker of risk of post‐transplant lymphoproliferative disorders
Author(s) -
Agbalika Felix,
Larghero Jerome,
Esperou Helene,
Marais Dominique,
Robin Marie,
Foïs Elena,
De Latour Régis Peffault,
Gluckman Eliane,
Rocha Vanderson,
Benbunan Marc,
Socié Gerard,
Marolleau JeanPierre
Publication year - 2007
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2006.06420.x
Subject(s) - immunology , medicine , lymphoproliferative disorders , transplantation , hematopoietic stem cell transplantation , antibody , serology , haematopoiesis , stem cell , virus , antigen , viral load , epstein–barr virus , lymphoma , biology , genetics
Summary The occurrence of post‐transplant lymphoproliferative disorders (PTLDs) after allogeneic haematopoietic stem cell transplantation (allo‐HSCT) represents a clinical problem. Pretransplant Epstein–Barr virus serological status and viral load was determined in 21 recipients and 28 control transplanted patients, with (+) and without (−) PTLD, respectively. Early‐antigen immunoglobulin G (EA‐IgG) was detected in 12/21 PTLD + patients, but only 2/28 PTLD − patients ( P = 0·00023, Odds ratio = 17·42). High viral load was detected in peripheral blood mononuclear cells at PTLD diagnosis, independently of deleted LMP1 . Detection of EA‐IgG in allo‐HSCT recipients pretransplantation might be considered as risk factor for PTLD development.